Form 4: BioXcel Therapeutics CFO Richard Steinhart Reports Stock Sales and RSU Transactions
SEC Form 4 Filing
Richard Steinhart, CFO of BioXcel Therapeutics, reports the sale of common stock and the vesting of restricted stock units (RSUs) in a recent SEC filing.
Summary
- Richard Steinhart, the CFO of BioXcel Therapeutics, filed a Form 4 with the SEC detailing changes in his beneficial ownership of the company's stock.
- On March 14, 2024, and March 15, 2024, Steinhart exercised Restricted Stock Units (RSUs) converting them into common stock.
- Specifically, 521 RSUs vested on March 14, 2024, and 2,250 RSUs vested on March 15, 2024.
- On April 4, 2024, Steinhart sold 1,069 shares of common stock at a weighted average price of $2.635 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Steinhart directly owns 4,765 shares of common stock and 6,750 RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in financial analysis.
- Comparing the trading activity of BioXcel Therapeutics' executives to those of similar companies in the biotechnology sector can provide insights into relative valuation and sentiment.
- Companies like Amgen, Biogen, and Gilead Sciences are often used as benchmarks for comparison in the biotech industry.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The vesting of RSUs and subsequent sale of shares by the CFO could be perceived as a lack of confidence in the company's future prospects, although it is part of a pre-arranged plan.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-03-15 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-12-14 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2024-03-14 | Date of RSU vesting (521 shares) and conversion to common stock. |
| 2024-03-15 | Date of RSU vesting (2,250 shares) and conversion to common stock. |
| 2024-04-04 | Date of common stock sale (1,069 shares). |
| 2024-04-08 | Date of Form 4 filing. |
Keywords
Form 4, BioXcel Therapeutics, Richard Steinhart, BTAI, Stock Sale, RSU, Beneficial Ownership, SEC Filing, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.